GW Pharma’s Justin Gover on marketing the first cannabis-based drug
11 questions for the GW CEO on the watershed moment.
Regulatory
FDA reprimands Pfizer for leaving risk information out of Estring video
The Office of Prescription Drug Promotion has sent its second warning letter of the year.
Three quarters of Americans support listing drug prices in DTC ads: Kaiser survey
Across the political spectrum, most Americans favor President Donald Trump’s proposal to show drug prices in advertisements.
FDA just approved the first prescription drug derived from marijuana: 4 outstanding questions
The approval answers one question but raises others.
Confusion expected in wake of ‘Right to Try’ bill’s signing
It’s still entirely up to drugmakers whether they want to make their products available on an experimental basis. Patients may not see it that way.
FDA guidelines for payer, off-label communications: OK as long as ‘truthful’
Two FDA guidance documents aim to help pharma companies show the value of their drugs to payers beyond what’s included in FDA labeling.
GMHC takes Blood Equality push overseas
For the first time, the nonprofit is trying to eliminate bans on gay and bisexual men donating blood in countries other than the U.S.
AstraZeneca reprimanded by UK drug regulator for ‘misleading’ press release
A UK drug regulator has ruled that a 2017 press release from AstraZeneca was “misleading” as data “had not been presented in a balanced way”, following a complaint from a fellow pharma firm.
Marijuana: a green grey zone for patients, doctors, and pharma companies
Legalization of the drug for medical use is already having an impact on prescription patterns. But for patients and doctors alike, there are a lot of unanswered questions.
GDPR: How to make sure your business is ready
As of May 25, Europe’s groundbreaking General Data Protection Regulation (GDPR) will take effect, fundamentally changing the way businesses and government agencies deal with personal data.
Want to read more?
Please login or register first to view this content.
